FCM
CCCC icon

Farallon Capital Management’s C4 Therapeutics CCCC Stock Holding History

Farallon Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,000
Closed -$73.6K – 106
2026
Q1 		$73.6K Hold
28,000
– – ﹤0.01% 164
2025
Q4 		$53.5K Hold
28,000
– – ﹤0.01% 150
2025
Q3 		$62.2K Hold
28,000
– – ﹤0.01% 136
2025
Q2 		$40K Hold
28,000
– – ﹤0.01% 140
2025
Q1 		$44.8K Hold
28,000
– – ﹤0.01% 141
2024
Q4 		$101K Hold
28,000
– – ﹤0.01% 143
2024
Q3 		$160K Hold
28,000
– – ﹤0.01% 148
2024
Q2 		$129K Hold
28,000
– – ﹤0.01% 148
2024
Q1 		$229K Buy
+28,000
New +$217K ﹤0.01% 142

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Farallon Capital Management's CCCC Position: Q2 2026 in Review

Farallon Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 28,000 shares — an estimated $73.6K sold.

Farallon Capital Management first reported a position in CCCC in Q1 2024 and held it in 9 quarters. The position peaked at $229K in Q1 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Farallon Capital Management reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Farallon Capital Management sold 28,000 C4 Therapeutics shares in Q2 2026, an estimated $73.6K.
  • Farallon Capital Management first reported a position in C4 Therapeutics in Q1 2024 and held it in 9 quarters.
  • Farallon Capital Management's C4 Therapeutics position peaked at $229K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.